Is atomoxetine effective in some comorbid mental disorders in ADHD?-Reference-Cited by-同舟云学术

Is atomoxetine effective in some comorbid mental disorders in ADHD?

Published:2016-09-01 Issue:1 Volume:63 Page:29-32
ISSN:2453-6725
Container-title:European Pharmaceutical Journal
language:en
Short-container-title:

Author:

Cesneková D.¹²,Šnircová E.³,Nosáľová G.⁴⁵,Ondrejka I.³

Affiliation:

1. Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Clinic of Psychiatry Slovakia

2. Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Department of Pharmacology, Slovakia

3. Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Clinic of Psychiatry, Slovakia

4. Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Department of Pharmacology Slovakia

5. Comenius University in Bratislava, Jessenius faculty of medicine in Martin, Biomedical Center Martin, Slovakia

Abstract

Abstract Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common comorbid disorder co-existing with ADHD. Atomoxetine is worldwide approved for treatment of ADHD in paediatric population; in addition atomoxetine is effective and safe in treatment of some comorbid disorders in ADHD. Pharmacotherapy of depression is limited and residual symptoms are common. Fluoxetine is currently considered to be the gold standard of treatment of depression, but effectiveness of acute phase of treatment is not sufficient. Atomoxetine as a selective noradrenaline reuptake inhibitor or olanzapine as a multi receptors antagonist drug in combination with fluoxetine could be perspective augmented treatment strategy of depression just for their antidepressant effect. The aim of our following study is to evaluate and compare effectiveness and safety of monotherapy and combined/augmented therapy in acute phase of depression treatment in adolescence, as well as introduce complex modern research methodology of effectiveness and safety of treatment.

Publisher

Walter de Gruyter GmbH

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference19 articles.

1. [1] American Psychiatric Association (APA). Disorders usually first diagnosed in infancy, childhood, or adolescence. Diagnostic and statistical manual of mental disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association. 2000.

2. [2] Bangs ME, Graham JE, Thomas JS et al.: Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407-420.

3. [3] Barton, J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90(suppl. L):126-129.

4. [4] Biederman J, Faraone S, Milberger S et al. A prospective 4-year follow-up study of attention deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53:437-446.

5. [5] DeFillipis M, Wagner KD. Management of Treatment-Resistant Depression in Children and Adolescents. Pediatr Drugs. 2014;16:353-361.